Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)
Related Experiment Video
Updated: Dec 13, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Xiaomin Wu1, Xiaojing Zhang2, Leilei Tao1
1Department of Oncology, Yancheng No.1 People's Hospital, the Affiliated Hospital of Nanjing University, 166 Yulong West Road, Yancheng, 224200, People's Republic of China.
Background:
Pulmonary high-grade neuroendocrine carcinoma (HGNEC) has a rising incidence of developing second primary malignancies (SPMs). This study is the first population-based analysis to quantify the SPM risks among survivors of lung HGNEC.
Methods:
We used the Surveillance, Epidemiology, and End Results (SEER) database to calculate standardized incidence ratio (SIR) and absolute excess risk (AER) between 2000 and 2016 for patients with pulmonary HGNEC.
Results:
The data of 1161 patients with SPMs were retrieved from the SEER database. The ratio of observed/expected number of SPMs in pulmonary HGNEC was 1.53. Solid tumours comprised 91% of all second malignancies in lung HGNEC patients, with the most common cancers reported in the oral cavity and pharynx, the urinary and respiratory systems CONCLUSIONS: Our study observed an increased risk of SPMs among patients with pulmongnancies.
